172 related articles for article (PubMed ID: 32473133)
21. Dibenzofuran Derivatives Inspired from Cercosporamide as Dual Inhibitors of Pim and CLK1 Kinases.
Dao VH; Ourliac-Garnier I; Logé C; McCarthy FO; Bach S; da Silva TG; Denevault-Sabourin C; Thiéfaine J; Baratte B; Robert T; Gouilleux F; Brachet-Botineau M; Bazin MA; Marchand P
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770981
[TBL] [Abstract][Full Text] [Related]
22. A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas.
Foulks JM; Carpenter KJ; Luo B; Xu Y; Senina A; Nix R; Chan A; Clifford A; Wilkes M; Vollmer D; Brenning B; Merx S; Lai S; McCullar MV; Ho KK; Albertson DJ; Call LT; Bearss JJ; Tripp S; Liu T; Stephens BJ; Mollard A; Warner SL; Bearss DJ; Kanner SB
Neoplasia; 2014 May; 16(5):403-12. PubMed ID: 24953177
[TBL] [Abstract][Full Text] [Related]
23. Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitors.
Wurz RP; Sastri C; D'Amico DC; Herberich B; Jackson CLM; Pettus LH; Tasker AS; Wu B; Guerrero N; Lipford JR; Winston JT; Yang Y; Wang P; Nguyen Y; Andrews KL; Huang X; Lee MR; Mohr C; Zhang JD; Reid DL; Xu Y; Zhou Y; Wang HL
Bioorg Med Chem Lett; 2016 Nov; 26(22):5580-5590. PubMed ID: 27769621
[TBL] [Abstract][Full Text] [Related]
24. Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors.
Pettus LH; Andrews KL; Booker SK; Chen J; Cee VJ; Chavez F; Chen Y; Eastwood H; Guerrero N; Herberich B; Hickman D; Lanman BA; Laszlo J; Lee MR; Lipford JR; Mattson B; Mohr C; Nguyen Y; Norman MH; Powers D; Reed AB; Rex K; Sastri C; Tamayo N; Wang P; Winston JT; Wu B; Wu T; Wurz RP; Xu Y; Zhou Y; Tasker AS; Wang HL
J Med Chem; 2016 Jul; 59(13):6407-30. PubMed ID: 27285051
[TBL] [Abstract][Full Text] [Related]
25. New Quinoxaline Derivatives as Dual Pim-1/2 Kinase Inhibitors: Design, Synthesis and Biological Evaluation.
Oyallon B; Brachet-Botineau M; Logé C; Robert T; Bach S; Ibrahim S; Raoul W; Croix C; Berthelot P; Guillon J; Pinaud N; Gouilleux F; Viaud-Massuard MC; Denevault-Sabourin C
Molecules; 2021 Feb; 26(4):. PubMed ID: 33562106
[TBL] [Abstract][Full Text] [Related]
26. Identification of novel inhibitors for Pim-1 kinase using pharmacophore modeling based on a novel method for selecting pharmacophore generation subsets.
Shahin R; Swellmeen L; Shaheen O; Aboalhaija N; Habash M
J Comput Aided Mol Des; 2016 Jan; 30(1):39-68. PubMed ID: 26685860
[TBL] [Abstract][Full Text] [Related]
27. Potential Pharmacological Inhibitors of Pim Kinase Under Clinical Trials.
Jeyapal GP; Chandrasekar MJN; Krishnasamy R; Selvaraj J; Mohammad M; Nanjan MJ
Anticancer Agents Med Chem; 2018; 18(8):1100-1114. PubMed ID: 29384063
[TBL] [Abstract][Full Text] [Related]
28. PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth.
Singh N; Padi SKR; Bearss JJ; Pandey R; Okumura K; Beltran H; Song JH; Kraft AS; Olive V
Mol Oncol; 2020 May; 14(5):974-990. PubMed ID: 32146726
[TBL] [Abstract][Full Text] [Related]
29. Pim-selective inhibitor DHPCC-9 reveals Pim kinases as potent stimulators of cancer cell migration and invasion.
Santio NM; Vahakoski RL; Rainio EM; Sandholm JA; Virtanen SS; Prudhomme M; Anizon F; Moreau P; Koskinen PJ
Mol Cancer; 2010 Oct; 9():279. PubMed ID: 20958956
[TBL] [Abstract][Full Text] [Related]
30. New potent and selective inhibitor of Pim-1/3 protein kinases sensitizes human colon carcinoma cells to doxorubicin.
Moreau P; Dezhenkova LG; Anizon F; Nauton L; Thery V; Liang S; Kaluzhny DN; Shtil AA
Anticancer Agents Med Chem; 2014; 14(9):1228-36. PubMed ID: 25175798
[TBL] [Abstract][Full Text] [Related]
31. PIM kinases 1, 2 and 3 in intracellular LIF signaling, proliferation and apoptosis in trophoblastic cells.
Mary Photini S; Chaiwangyen W; Weber M; Al-Kawlani B; Favaro RR; Jeschke U; Schleussner E; Morales-Prieto DM; Markert UR
Exp Cell Res; 2017 Oct; 359(1):275-283. PubMed ID: 28729093
[TBL] [Abstract][Full Text] [Related]
32. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
[TBL] [Abstract][Full Text] [Related]
33. Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition.
Blanco-Aparicio C; Collazo AM; Oyarzabal J; Leal JF; Albarán MI; Lima FR; Pequeño B; Ajenjo N; Becerra M; Alfonso P; Reymundo MI; Palacios I; Mateos G; Quiñones H; Corrionero A; Carnero A; Pevarello P; Lopez AR; Fominaya J; Pastor J; Bischoff JR
Cancer Lett; 2011 Jan; 300(2):145-53. PubMed ID: 21051136
[TBL] [Abstract][Full Text] [Related]
34. Fighting tumor cell survival: advances in the design and evaluation of Pim inhibitors.
Anizon F; Shtil AA; Danilenko VN; Moreau P
Curr Med Chem; 2010; 17(34):4114-33. PubMed ID: 20939820
[TBL] [Abstract][Full Text] [Related]
35. Anti‑survival and pro‑apoptotic effects of meridianin C derivatives on MV4‑11 human acute myeloid leukemia cells.
Cho H; Yadav AK; Do Y; Heo M; Bishop-Bailey D; Lee J; Jang BC
Int J Oncol; 2020 Jan; 56(1):368-378. PubMed ID: 31789392
[TBL] [Abstract][Full Text] [Related]
36. A serine/threonine protein PIM kinase as a biomarker of cancer and a target for anti-tumor therapy.
Panchal NK; Sabina EP
Life Sci; 2020 Aug; 255():117866. PubMed ID: 32479955
[TBL] [Abstract][Full Text] [Related]
37. Discovery of novel (+)-Usnic acid derivatives as potential anti-leukemia agents with pan-Pim kinases inhibitory activity.
Wang S; Zang J; Huang M; Guan L; Xing K; Zhang J; Liu D; Zhao L
Bioorg Chem; 2019 Aug; 89():102971. PubMed ID: 31200288
[TBL] [Abstract][Full Text] [Related]
38. PIM-1 kinase inhibitor SMI-4a exerts antitumor effects in chronic myeloid leukemia cells by enhancing the activity of glycogen synthase kinase 3β.
Fan RF; Lu Y; Fang ZG; Guo XY; Chen YX; Xu YC; Lei YM; Liu KF; Lin DJ; Liu LL; Liu XF
Mol Med Rep; 2017 Oct; 16(4):4603-4612. PubMed ID: 28849186
[TBL] [Abstract][Full Text] [Related]
39. Discovery and evaluation of 3,5-disubstituted indole derivatives as Pim kinase inhibitors.
More KN; Hong VS; Lee A; Park J; Kim S; Lee J
Bioorg Med Chem Lett; 2018 Aug; 28(14):2513-2517. PubMed ID: 29871845
[TBL] [Abstract][Full Text] [Related]
40. [The Pim family of protein kinases: structure, functions and roles in hematopoietic malignancies].
Zhukova IuN; Alekseeva MG; Zakharevich NV; Shtil' AA; Danilenko VN
Mol Biol (Mosk); 2011; 45(5):755-64. PubMed ID: 22393773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]